+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Cost-effectiveness analysis of GOELAM SA3, a randomized placebo-controlled protocol of GM-SCF for elderly patients with acute myeloid leukemia



Cost-effectiveness analysis of GOELAM SA3, a randomized placebo-controlled protocol of GM-SCF for elderly patients with acute myeloid leukemia



Blood 90(10 SUPPL 1 PART 1): 72A, Nov 15




(PDF emailed within 1 workday: $29.90)

Accession: 030737337

Download citation: RISBibTeXText


Related references

Cost effectiveness of GM-CSF in the treatment of acute myeloblastic leukemia in aged patients: protocol of GOELAM Sa3. Therapie 56(2): 131-133, 2001

Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial. Journal of Clinical Oncology 31(25): 3110-3118, 2013

Impact of aerobic exercise training during chemotherapy on cancer related cognitive impairments in patients suffering from acute myeloid leukemia or myelodysplastic syndrome - Study protocol of a randomized placebo-controlled trial. Contemporary Clinical Trials 49: 1-5, 2017

A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM). Blood 91(8): 2722-2730, 1998

European multicentre phase III randomized placebo-controlled study of lenograstim recombinant glycosylated human granulocyte colony stimulating factor in elderly patients with de novo acute myeloid leukemia. British Journal of Haematology 87(SUPPL 1): 154, 1994

The safety, effectiveness and cost-effectiveness of cytisine in achieving six-month continuous smoking abstinence in tuberculosis patients-protocol for a double-blind, placebo-controlled randomized trial. Addiction 2018, 2018

A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group. Blood 90(12): 4710-4718, 1998

GM-CSF in a double-blind randomized, placebo controlled trial in therapy of adult patients with de novo acute myeloid leukemia. Annals of Hematology 65(SUPPL ): A67, 1992

Gm csf in a double blind randomized placebo controlled trial in therapy of adult patients with de novo acute myeloid leukemia aml. Experimental Hematology (Charlottesville) 20(6): 786, 1992

GM-CSF in a double-blind randomized, placebo controlled trial in therapy of adult patients with de novo acute myeloid leukemia (AML). Leukemia 9(1): 3-9, 1995

A multi-center, randomized controlled clinical trial, cost-effectiveness and qualitative research of electroacupuncture with usual care for patients with non-acute pain after back surgery: study protocol for a randomized controlled trial. Trials 19(1): 65, 2018

A network meta-analysis of randomized controlled trials of induction treatments in acute myeloid leukemia in the elderly. Clinical Therapeutics 33(3): 254-279, 2011

Quinine given as an MDR reversing agent in the treatment of adult acute myeloid leukemia Results of the randomized GOELAM 2 trial. Blood 96(11 Part 1): 504a-505a, November 16, 2000

A double blind placebo controlled trial of G-CSF in elderly patients with previously untreated acute myeloid leukemia A southwest oncology group study. Blood 86(10 SUPPL 1): 434A, 1995

Cost-effectiveness and quality-of-life assessment of GM-CSF as an adjunct to intensive remission induction chemotherapy in elderly patients with acute myeloid leukemia. British Journal of Haematology 100(4): 629-636, 1998